Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Trevi Therapeutics

Request full access

Develops drugs for treating uremic pruritus

New Haven, United StatesFounded 2011Biotech & Life Sciences

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing the development and commercialization of its investigational therapy, Haduvio™ (nalbuphine ER). The company was established in 2011 by Jennifer L. Good and Dr. Thomas R. Sciascia and is headquartered in New Haven, Connecticut. The co-founders had previously worked together at Penwest Pharmaceuticals, where Ms. Good served as CEO and Dr. Sciascia was Chief Medical Officer. After Penwest was acquired, they identified the potential in nalbuphine, a compound from their former company, and negotiated to acquire it, leading to the formation of Trevi. Ms. Good, who has been President and CEO since the company's inception, brought a background in finance and accounting, including experience at Ernst & Young, while Dr. Sciascia provided the neurological expertise.

As a clinical-stage entity, Trevi Therapeutics does not yet generate revenue from product sales; its operations are funded through financing activities like stock offerings. The company successfully went public with an initial public offering (IPO) on the Nasdaq on May 7, 2019, under the ticker TRVI, raising approximately $55 million. Subsequent offerings, including a $115 million financing in June 2025, have extended the company's financial runway into 2029, supporting its late-stage clinical development. The business model is centered on advancing Haduvio through rigorous clinical trials to gain regulatory approval, which would then allow for commercialization and sales to patients. The company operates in the biopharmaceutical market, focusing on patient populations with significant unmet medical needs.

Trevi's sole product candidate, Haduvio™, is an oral extended-release formulation of nalbuphine, a drug with a long history of use for pain management. Haduvio features a dual mechanism of action, functioning as a kappa opioid receptor agonist and a mu opioid receptor antagonist. This unique profile allows it to target the body's central and peripheral nervous systems to address the underlying pathophysiology of certain conditions without the high potential for abuse associated with typical mu-opioid agonists. Initially, Trevi explored its use in multiple indications, including severe itching (pruritus) and levodopa-induced dyskinesia in Parkinson's patients. Following compelling clinical data, the company has pivoted to focus squarely on chronic cough conditions. Positive results from its Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) and its Phase 2a RIVER trial for refractory chronic cough (RCC) have demonstrated statistically significant reductions in cough frequency, reinforcing the company's strategic direction. Trevi is now preparing for Phase 3 trials, aiming to be the first approved therapy for chronic cough in IPF patients.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2011
Headquarters
New Haven, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Outcome tier
Unicorn$1–10B valuation tier

Trevi Therapeutics in the New Haven ecosystem

Live from Dealroom

The Trevi Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later9 investors entered at this stage

  • Solar capital
  • Square 1 Bank
  • NEA
  • Lundbeckfonden Ventures
  • Omega Funds
  • Aperture Venture Partners
  • Frazier Healthcare Partners
  • Venrock Healthcare Capital Partners
  • Fairmount Funds Management
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
5K monthly visits
across markets
🇺🇸 United States86%
🇮🇳 India14%
🇵🇭 Philippines0%
Top 3 markets shown

Patents

Estimated portfolio value
$18M

13 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Trevi Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Trevi Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.